CRISPR gene editing stocks fall after Editas CEO resignsShares in firms developing therapies based on CRISPR gene editing technology have fallen after the resignation of the Share XCRISPR gene editing stocks fall after Editas CEO resignshttps://pharmaphorum.com/news/crispr-gene-editing-stocks-fall-after-editas-ceo-resigns/
